What did @nattyprotocol actually say?
The creator argued that combining retatrutide (referred to as "RETA TrueTide") with CJC-1295 and ipamorelin is, for most people, "an extremely potent fat burning combo with a very favorable side effect profile." The core logic: the GH secretagogue stack boosts growth hormone and IGF-1 to drive fat loss, while the GLP-1 component offsets any insulin sensitivity concerns the IGF-1 elevation might cause. They also mentioned adding retatrutide to a "NAD+ cheat sheet," implying this is a curated optimization protocol.
This is not a casual off-the-cuff take. The creator is clearly familiar with the pharmacology here, and that familiarity is part of what makes the video worth examining closely. Getting the mechanism mostly right while glossing over regulatory and safety complexity is its own kind of problem.
Does the science back this up?
Partially, but with real gaps the video does not address. The GH-boosting effect of CJC-1295 combined with ipamorelin is reasonably well-supported. The insulin sensitivity claim about GLP-1 receptor agonists is also grounded in evidence, but retatrutide is not simply a GLP-1 drug.
On CJC-1295 and ipamorelin: Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed CJC-1295 elevated IGF-1 levels by 28-43% and sustained elevated GH secretion. Ipamorelin's cleaner GH pulse profile with less cortisol and prolactin spillover compared to older GHRPs is documented in Raun et al. (1998, European Journal of Endocrinology). The "relatively natural GH-to-IGF-1 ratio" point has some backing here.
On retatrutide specifically: it is a triagonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 data published by Jastreboff et al. (2023, New England Journal of Medicine) showed up to 17.5% body weight reduction at 48 weeks, which is striking. But the glucagon receptor agonism adds metabolic complexity the creator skips entirely, including potential effects on hepatic glucose output and heart rate. Calling its side effect profile simply "favorable" undersells what patients in trials actually experienced.
What did they get wrong (or right)?
They got the basic mechanistic logic directionally right. GLP-1 receptor agonism does improve insulin sensitivity, and that partially counteracts the insulin resistance risk from elevated IGF-1. That is a fair and reasonably accurate point.
Where this falls apart: retatrutide is not approved by the FDA. It completed Phase 2 trials as of 2023 and has not cleared Phase 3 as of this writing. Compounded versions sold under names like "TrueTide" are not equivalent to the investigational drug used in Jastreboff et al. (2023). The creator blurs this line completely, treating compounded retatrutide as interchangeable with a clinical trial compound.
The claim that the combo has a "very favorable side effect profile" is also doing a lot of heavy lifting. Retatrutide's glucagon agonism raises heart rate as a documented concern in trial data. Adding exogenous GH axis stimulation on top of an already aggressive fat-loss agent in people who may not be metabolically screened is not something any published study has evaluated. The creator presents a theoretical mechanism as if it has been validated in combination. It has not.
What should you actually know?
Three things matter here. First, retatrutide is not an approved drug anywhere. Compounded versions exist in a legal and quality gray zone. The Phase 2 data is genuinely impressive, but Phase 2 is not approval, and compounded peptides are not subject to the same manufacturing standards as clinical trial materials.
Second, the GH secretagogue stack this creator recommends alongside retatrutide has not been studied in combination with any GLP-1-class agent in a controlled trial. The mechanistic argument is plausible. Plausible is not the same as tested.
Third, IGF-1 elevation is not a trivial concern to wave away with "fortunately, GLP-1s enhance insulin sensitivity." Chronically elevated IGF-1 has associations with cancer risk in epidemiological data, including meta-analyses by Renehan et al. (2004, The Lancet). This goes unmentioned entirely.
If you are considering any of these compounds, that conversation belongs with a physician who can review your metabolic labs, not a TikTok comment section.